Outcome measures in placebo-controlled trials of osteoarthritis: Responsiveness to treatment effects in the REPORT database

Osteoarthritis and Cartilage

Volumn 19, Issue 5, 2011, Pages 483-492

  Dworkin, R H ^a   Peirce Sandner, S ^a   Turk, D C ^b   McDermott, M P ^a   Gibofsky, A ^c   Simon, L S ^d   Farrar, J T ^e   Katz, N P ^f,g  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d SDG LLC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Analgesic Solutions   (United States)

^g TUFTS UNIVERSITY   (United States)

Author keywords

Osteoarthritis; Outcome measures; Randomized clinical trials; Responsiveness; Standardized effect size; Treatment effect

Indexed keywords

CHONDROITIN; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO;

ARTICLE; COCHRANE LIBRARY; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; HIP OSTEOARTHRITIS; HUMAN; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; MEDLINE; META ANALYSIS; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; TREATMENT RESPONSE;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; OSTEOARTHRITIS; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79955811330     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2011.02.020     Document Type: Article

References (58)

1. Bjordal J.M., Klovning A., Ljunggren A.E., Slørdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007, 11:125-138.
2. Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
3. U.S. Department of Health and Human Services. Guidance for industry: E10 choice of control group and related issues in clinical trials, 2001; Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073139.pdf.
4. U.S. Department of Health and Human Services. Guidance for industry: clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA), 1999; Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071579.pdf.
5. Pham T., van der Heijde D., Altman R.D., Anderson J.J., Bellamy N., Hochberg M., et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004, 12:389-399.
6. European Medicines Agency. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis, 2009; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003443.pdf.
7. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
8. Lequesne M.G., Mery C., Samson M., Gerard P. Indexes of severity for osteoarthritis of the hip and knee: validation: value in comparison with other assessment tests. Scand J Rheumatol 1987, 65(Suppl):85-89.
9. Altman R., Brandt K., Hochberg M., Moskowitz R., Bellamy N., Bloch D.A., et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996, 4:217-243.
10. Bellamy N., Kirwan J., Boers M., Brooks P., Strand V., Tugwell P., et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997, 24:799-802.
11. Dougados M., Leclaire P., van der Heijde D., Bloch D.A., Bellamy N., Altman R.D. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative. Osteoarthritis Cartilage 2000, 8:395-403.
12. Maheu E., Altman R.D., Bloch D.A., Doherty M., Hochberg M., Mannoni A., et al. Design and conduct of clinical trials in patients with osteoarthritis of the hand: recommendations from a task force of the Osteoarthritis Research Society International. Osteoarthritis Cartilage 2006, 14:303-322.
13. Turk D.C., Dworkin R.H., Allen R.R., Bellamy N., Brandenburg N., Carr D.B., et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003, 106:337-345.
14. Dworkin R.H., Turk D.C., Farrar J.T., Haythornthwaite J.A., Jensen M.P., Katz N.P., et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005, 113:9-19.
15. Turk D.C., Dworkin R.H., Burke L.B., Gershon R., Rothman M., Scott J., et al. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 2006, 125:208-215.
16. Dworkin R.H., Turk D.C., Wyrwich K.W., Beaton D., Cleeland C.S., Farrar J.T., et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008, 9:105-121.
17. Dworkin R.H., Turk D.C., McDermott M.P., Peirce-Sandner S., Burke L.B., Cowan P., et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 2009, 146:238-244.
18. Dworkin R.H., Turk D.C., Peirce-Sandner S., McDermott M.P., Farrar J.T., Hertz S., et al. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain 2010, 150:12-16.
19. Dworkin RH, Turk DC, Katz NP, Rowbotham MC, Peirce-Sandner S, Cerny I Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain 2011, 152(Suppl):S107-S115.
20. Zhang W., Robertson J., Jones A.C., Dieppe P.A., Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008, 67:1716-1723.
21. Trijau S., Avouac J., Escalas C., Gossec L., Dougados M. Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010, 18:1012-1018.
22. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2, 2009; Available at: http://www.mrc-bsu.cam.ac.uk/cochrane/handbook.
23. National Collaborating Centre for Chronic Conditions Osteoarthritis: National Clinical Guideline for Care and Management in Adults 2008, Royal College of Physicians, London.
24. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
25. Wood L., Egger M., Gluud L.L., Schulz K.F., Jüni P., Altman D.G., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008, 336:601-605.
26. Faucher M., Poiraudeau S., Lefevre-Colau M.M., Rannou F., Fermanian J., Revel M. Algo-functional assessment of knee osteoarthritis: comparison of the test-retest reliability and construct validity of the WOMAC and Lequesne indexes. Osteoarthritis Cartilage 2002, 10:602-610.
27. Normand S.L. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999, 18:321-359.
28. Whitehead A. Meta-analysis of Controlled Clinical Trials 2002, John Wiley, Chichester, UK.
29. Gentelle-Bonnassies S., Le Claire P., Mezieres M., Ayral X., Dougados M. Comparison of the responsiveness of symptomatic outcome measures in knee osteoarthritis. Arthritis Care Res 2000, 13:280-285.
30. Krebs E.E., Bair M.J., Damush T.M., Tu W., Wu J., Kroenke K. Comparative responsiveness of pain outcome measures among primary care patients with musculoskeletal pain. Med Care 2010, 48:1007-1014.
31. Bellamy N. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol 2002, 29:2473-2476.
32. Villanueva I., del Mar Guzman M., Javier Toyos F., Ariza-Ariza R., Navarro F. Relative efficiency and validity properties of a visual analogue vs a categorical scaled version of the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index: Spanish versions. Osteoarthritis Cartilage 2004, 12:225-231.
33. Bellamy N., Campbell J., Syrotuik J. Comparative study of self-rating pain scales in osteoarthritis patients. Curr Med Res Opin 1999, 15:113-119.
34. Bolognese J.A., Schnitzer T.J., Ehrich E.W. Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. Osteoarthritis Cartilage 2003, 11:499-507.
35. Lund I., Lundeberg T., Sandberg L., Budh C.N., Kowalski J., Svensson E. Lack of interchangeability between visual analogue and verbal rating pain scales: a cross sectional description of pain etiology groups. BMC Med Res Methodol 2005, 5:31.
36. Dworkin R.H., Jensen M.P., Gould E., Jones B.A., Xiang Q., Galer B.S., et al. Treatment satisfaction in osteoarthritis and low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. J Pain 2011, 12:416-424.
37. Bingham C.O., Bird S.R., Smugar S.S., Xu X., Tershakovec A.M. Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. Osteoarthritis Cartilage 2008, 16:1289-1293.
38. Carville S.F., Choy E.H.S. Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia. J Rheumatol 2008, 35:2094-2105.
39. Dunkl P.R., Taylor A.G., McConnell G.G., Alfano A.P., Conaway M.R. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000, 27:2683-2691.
40. Angst F., Aeschlimann A., Steiner W., Stucki G. Responsiveness of the WOMAC osteoarthritis index as compared with the SF-36 in patients with osteoarthritis of the legs undergoing a comprehensive rehabilitation intervention. Ann Rheum Dis 2001, 60:834-840.
41. Soohoo N.F., Vyas R.M., Samimi D.B., Molina R., Lieberman J.R. Comparison of the responsiveness of the SF-36 and WOMAC in patients undergoing total hip arthroplasty. J Arthroplasty 2007, 22:1168-1173.
42. Quessy S.N., Rowbotham M.C. Placebo response in neuropathic pain trials. Pain 2008, 138:479-483.
43. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005, 65:S32-S49.
44. Katz J., Finnerup N.B., Dworkin R.H. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology 2008, 70:263-272.
45. Wandel S., Jüni P., Tendal B., Nüesch E., Villiger P.M., Welton N.J., et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010, 341. c4675.
46. Pelletier J.-P., Hochberg M.C., du Souich P., Kahan A., Michel B.A. Effect size is encouraging. BMJ 2010, 341. c6328.
47. Rowbotham M.C. The impact of selective publication on clinical research in pain. Pain 2008, 140:401-404.
48. Rowbotham M.C. The case for publishing 'negative' trials. Pain 2009, 146:225-226.
49. Scott-Lennox J.A., McLaughlin-Miley C., Lennox R.D., Bohlig A.M., Cutler B.L., Yan C., et al. Stratification of flare intensity identifies placebo responders in a treatment efficacy trial of patients with osteoarthritis. Arthritis Rheum 2001, 44:1599-1607.
50. Allen K.D., Coffman C.J., Golightly Y.M., Stechuchak K.M., Voils C.I., Keefe F.J. Comparison of pain measures among patients with osteoarthritis. J Pain 2010, 11:522-527.
51. Bellamy N, Wilson C, Hendrikz J, Whitehouse S.L., Patel B, Dennison S Osteoarthritis Index delivered by mobile phone (m-WOMAC) is valid, reliable, and responsive. J Clin Epidemiol 2011, 64:182-190.
52. Tubach F., Ravaud P., Baron G., Falissard B., Logeart I., Bellamy N., et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005, 64:29-33.
53. Dougados M., Moore A., Yu S., Gitton X. Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomized, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis Res Ther 2007, 9. R11.
54. Bellamy N., Bell M.J., Goldsmith C.H., Lee S., Maschio M., Raynauld J.-P., et al. BLISS index using WOMAC index detects between-group differences at low-intensity symptom states in osteoarthritis. J Clin Epidemiol 2010, 63:566-574.
55. U.S. Department of Health and Human Services. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims, 2009; Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
56. Ruta D.A., Garratt A.M., Russell I.T. Patient centred assessment of quality of life for patients with four common conditions. Qual Health Care 1999, 8:22-29.
57. Clinch J., Tugwell P., Wells G., Shea B. Individualized functional priority approach to the assessment of health related quality of life in rheumatology. J Rheumatol 2001, 28:445-451.
58. Jolles B.M., Buchbinder R., Beaton D.E. A study compared nine patient-specific indices for musculoskeletal disorders. J Clin Epidemiol 2005, 58:791-801.